Company Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma.
The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Adrian H. Gottschalk |
Contact Details
Address: 500 Technology Square, Suite 700 Cambridge, Massachusetts 02139 United States | |
| Phone | 617 586 3100 |
| Website | foghorntx.com |
Stock Details
| Ticker Symbol | FHTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001822462 |
| CUSIP Number | 344174107 |
| ISIN Number | US3441741077 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Karin Hellsvik | Chief of Staff to the Chief Executive Officer, Vice President of Corporate Affairs and Investor Relations |
| Adrian H. B. Gottschalk | President, Chief Executive Officer and Director |
| Kristian Humer M.B.A. | Chief Financial Officer |
| Dr. Anna Rivkin Ph.D. | Chief Business Officer |
| Dr. Gerald R. Crabtree M.d. | Founder and Member of Scientific Advisory Board |
| Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer |
| Michael J. LaCascia J.D. | Chief Legal Officer |
| Saurabh Sewak Ph.D. | Vice President of Corporate Development |
| Carlos Costa | Chief People Officer |
| Dr. Alfonso Quintas Cardama M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2025 | 10-Q | Quarterly Report |
| May 14, 2025 | 8-K | Current Report |
| May 5, 2025 | ARS | Filing |
| May 5, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 5, 2025 | DEF 14A | Other definitive proxy statements |
| May 1, 2025 | 8-K | Current Report |
| Apr 28, 2025 | 8-K | Current Report |
| Mar 24, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 424B5 | Filing |